Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 344 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intravenous Infection Clear all
Completed Not applicable Interventional

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

NCT00000684
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

NCT00002159
View directory record Official record
Conditions
HIV Infections, Histoplasmosis, Blastomycosis
Interventions
Itraconazole, Amphotericin B
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 2:33 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Or v IV Antibiotics for Infection

NCT04723940
View directory record Official record
Conditions
Joint Infection
Interventions
Bactrim, Cefadroxil, Doxycycline Hcl, Clindamycin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

NCT04720378
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

NCT01549002
View directory record Official record
Conditions
Abscess, Pain
Interventions
Intranasal Fentanyl, Intravenous Morphine
Drug
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675
View directory record Official record
Conditions
Infections, Gram-positive Bacterial
Interventions
Telavancin, vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 7, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

NCT04778059
View directory record Official record
Conditions
2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions
USB002, Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

PRO 140 by IV Administration in Adults With HIV-1 Infection

NCT00613379
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

NCT05515562
View directory record Official record
Conditions
Microbial Colonization
Interventions
Omadacycline Injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

NCT01744730
View directory record Official record
Conditions
Bacterial Infections, Obesity
Interventions
Clindamycin
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting No phase listed Observational

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

NCT05285735
View directory record Official record
Conditions
Pregnancy, Malaria
Interventions
Not listed
Lead sponsor
Amivas Inc.
Industry
Eligibility
15 Years to 100 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

NCT00458731
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bevacizumab, cediranib maleate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

NCT00002395
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Topotecan
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Results available

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
View directory record Official record
Conditions
Viral Disease
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Mountain View, California • Newport Beach, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

NCT00000722
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 7, 2026, 2:33 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

NCT01063933
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 7, 2026, 2:33 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 7, 2026, 2:33 PM EDT
Completed No phase listed Observational

Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.

NCT03913468
View directory record Official record
Conditions
Septic Shock, Ascorbic Acid Deficiency
Interventions
Intravenous Ascorbic Acid
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2Phase 3 Interventional

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

NCT00037206
View directory record Official record
Conditions
Aspergillosis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

NCT02607618
View directory record Official record
Conditions
Skin Structures and Soft Tissue Infections
Interventions
Iclaprim, Vancomycin
Drug
Lead sponsor
Motif Bio
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 7, 2026, 2:33 PM EDT